{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:12:24Z","timestamp":1762603944174},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.cmi.2015.02.003","type":"journal-article","created":{"date-parts":[[2015,2,11]],"date-time":"2015-02-11T01:22:10Z","timestamp":1423617730000},"page":"605.e1-605.e9","source":"Crossref","is-referenced-by-count":9,"title":["Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses"],"prefix":"10.1016","volume":"21","author":[{"given":"P.","family":"Rojas S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"de Mulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Fernandez-Cooke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Jim\u00e9nez de Ory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Jos\u00e9 Mellado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Tomas Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1.","family":"Holgu\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2015.02.003_bib1","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/01.inf.0000091282.70253.5f","article-title":"Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus\u2013infected children","volume":"22","author":"Sanchez","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2015.02.003_bib2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1086\/521167","volume":"45","author":"Judd","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2015.02.003_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/INF.0b013e31824580e8","article-title":"Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1\u2013infected children and adolescents","volume":"31","author":"Briz","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2015.02.003_bib4","first-page":"642","article-title":"2014 Update of the drug resistance mutations in HIV-1","volume":"22","author":"Wensing","year":"2014","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.cmi.2015.02.003_bib5","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1468-1293.2009.00759.x","article-title":"PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection","volume":"10","author":"Welch","year":"2009","journal-title":"HIV Med"},{"key":"10.1016\/j.cmi.2015.02.003_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/cid\/cit627","article-title":"Extraordinary heterogeneity of virological outcomes in patients receiving highly active antiretroviral therapy and monitored with the World Health Organization Public Health approach in Sub-Saharan Africa and Southeast Asia","volume":"58","author":"Aghokeng","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2015.02.003_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3851\/IMP2437","article-title":"Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review","volume":"18","author":"Stadeli","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cmi.2015.02.003_bib8","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/jac\/dku104","article-title":"Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review","volume":"69","author":"Rojas S\u00e1nchez","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2015.02.003_bib9","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(11)60208-0","article-title":"Risk of triple-class virological failure in children with HIV: a retrospective cohort study PLATO II","volume":"377","author":"Castro","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2015.02.003_bib10","first-page":"180","article-title":"Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice","volume":"13","author":"Imaz","year":"2011","journal-title":"AIDS Rev"},{"key":"10.1016\/j.cmi.2015.02.003_bib11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/135965350701200606","article-title":"Danish HIV cohort study genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure","volume":"12","author":"Lohse","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cmi.2015.02.003_bib12","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1093\/jac\/dkr305","article-title":"Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain","volume":"10","author":"de Mulder","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2015.02.003_bib13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/aid.2009.0122","article-title":"Pediatric HIV BioBank: a new role of the Spanish HIV BioBank in pediatric HIV research","volume":"26","author":"Garc\u00eda-Merino","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.cmi.2015.02.003_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/INF.0b013e3182678c7c","article-title":"Dynamics of drug resistance prevalence and susceptibility in the Madrid cohort of HIV-1-infected children: 1993\u20132010 analysis","volume":"11","author":"de Mulder","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2015.02.003_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/INF.0b013e31818c8d2c","article-title":"Tenofovir use in human immunodeficiency virus-1\u2013infected children in the United Kingdom and Ireland","volume":"28","author":"Riordan","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2015.02.003_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/135965350100603S03","article-title":"Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure","volume":"3","author":"Miller","year":"2001","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cmi.2015.02.003_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jama.288.2.169","article-title":"Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial","volume":"2","author":"Hammer","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2015.02.003_bib18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1472-8206.2011.01009.x","article-title":"Mechanism of HIV antiretroviral drugs progress toward drug resistance","volume":"26","author":"Ammaranond","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.cmi.2015.02.003_bib19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1086\/597760","article-title":"Establishment of drug-resistant HIV-1 in latent reservoirs","volume":"199","author":"Dahl","year":"2009","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2015.02.003_bib20","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/QAD.0b013e32835faa72","article-title":"The CD4\/CD8 ratio as a marker T-cell activation, senescence and activation\/exhaustion in treated HIV-infected children and young adults","volume":"27","author":"Sainz","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2015.02.003_bib21","first-page":"23","article-title":"Management of HIV infection after triple class failure","volume":"36","author":"Cossarini","year":"2013","journal-title":"New Microbiol"},{"key":"10.1016\/j.cmi.2015.02.003_bib22","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1089\/aid.2006.0298","article-title":"The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C\u2013infected adults treated with ZDV\/ddI-containing HAART in Southern Africa","volume":"23","author":"Novitsky","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.cmi.2015.02.003_bib23","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/cid\/cir967","article-title":"Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India","volume":"54","author":"Saravanan","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2015.02.003_bib24","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1128\/AAC.44.9.2475-2484.2000","article-title":"Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy","volume":"44","author":"Bacheler","year":"2000","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15002906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15002906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T06:44:42Z","timestamp":1651214682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X15002906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1198743X15002906"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2015.02.003","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}